Back to directory

Multiple Myeloma and Amyloidosis Program

University of North Carolina at Chapel Hill

AL Amyloidosis ATTRv ATTRwt AA Amyloidosis 1 Rare Subtype

Contact Information

Primary Contact

Sascha Tuchman

Program Lead / Physician

Activity level

  • Patients per year200
  • New diagnoses per year75

Multidisciplinary team

  • HematologyOn-site
  • CardiologyOn-site
  • NephrologyOn-site
  • NeurologyOn-site
  • PathologyOn-site
Other specialists
PulmonologyGenetic counsellorsNuclear medicine specialistsCardiac imaging specialistsTransplant programme - heartTransplant programme - kidneyTransplant programme - liverAllied health professionals (NP, PA)Palliative carePsychology / counsellingSocial work

Diagnostic capabilities

  • EchocardiographyOn-site
  • Cardiac MRI (CMR)On-site
  • Radionuclide imagingOn-site
  • Histopathology (Congo red)On-site
  • Amyloid typingThrough network partners
  • Genetic testingOn-site
  • Fat aspiration / labial gland biopsyOn-site
  • Organ biopsiesOn-site
Partner laboratories

Amyloid subtyping through mass spec via Mayo Clinic

Subtype expertise

  • ALYes
  • ATTRvYes
  • ATTRwtYes
  • AAYes
Rare subtypes
Localised amyloidosis
Referral pathways

Multi-disciplinary team evaluation and management as needed.

Treatment options

  • Chemotherapy (AL)Available on-site
  • TTR stabilizersAvailable on-site
  • RNA interferenceAvailable on-site
  • Antisense oligonucleotidesAvailable on-site
  • Stem cell transplantAvailable on-site
  • Heart transplantAvailable on-site
  • Kidney transplantAvailable on-site
  • Liver transplantAvailable on-site

Patient support services

Services offered
Psychosocial supportSocial workGenetic counsellingNutritional guidance (dietitian)Specialty pharmacyPatient support groupsPalliative careFinancial or access counselling

Networks & telemedicine

  • Telemedicine / virtual consultationYes
  • Part of a formal amyloidosis networkYes
  • Diagnostic services for other organisationsNo
Diagnostic services contact

Last confirmed: 13 March 2026

Listings are self-reported by each center and have not been independently verified by the International Society of Amyloidosis (ISA). Inclusion in this directory does not constitute certification, accreditation, or endorsement by ISA.